CDMRP Neurofibromatosis Exploration-Hypothesis Development Award
ID: 355147Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355147
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis Exploration-Hypothesis Development Award to support innovative research in neurofibromatosis (NF) types 1 and 2, as well as schwannomatosis. This grant aims to facilitate high-risk, high-reward studies that can lead to groundbreaking advancements in NF understanding, diagnosis, and treatment, particularly benefiting military personnel and their families. The total funding available for this program is $1,120,000, with up to $100,000 awarded per project over a two-year period, and applications must be submitted in two phases: a pre-application by September 12, 2024, and a full application by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524NFRPEHDA_GG.pdf
    The Department of Defense (DOD) is announcing the FY24 Neurofibromatosis Exploration-Hypothesis Development Award as part of the Neurofibromatosis Research Program. This funding aims to support innovative research related to neurofibromatosis (NF) types 1 and 2 and schwannomatosis, ultimately improving diagnosis and treatment. The award offers up to $100,000 over a two-year period, with a total appropriation of $25 million for FY24. Applications must undergo a two-step submission process, including a pre-application due by September 12, 2024, and full applications due by October 3, 2024. Key areas of emphasis include advancements in NF understanding, technological innovation, and health services research pertinent to military personnel and their families. Applicants are encouraged to foster collaboration across disciplines and organizations. Peer review will evaluate the merit based on innovation, research strategy, and potential impact. Compliance with institutional requirements, data sharing, and rigorous study design is mandated. The program seeks to facilitate high-risk, high-reward research that significantly impacts NF research and patient care, demonstrating DOD's commitment to addressing critical health challenges faced by service members and the broader community.
    Similar Opportunities
    CDMRP Neurofibromatosis Investigator-Initiated Research Program
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis Investigator-Initiated Research Program (NFRP) grant to support innovative research projects focused on neurofibromatosis (NF). This program aims to enhance understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis, with a particular emphasis on improving the quality of life for affected individuals, including military personnel and veterans. The total estimated funding for this initiative is $5.36 million, with up to six awards anticipated, and applications must be submitted by October 3, 2024, following a pre-application deadline of September 12, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    CDMRP Neurofibromatosis Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 Neurofibromatosis Clinical Trial Award to support innovative clinical trials aimed at addressing high-impact issues related to neurofibromatosis (NF), including NF1, NF2, and schwannomatosis. Applicants are required to present a clear clinical trial design, preliminary data, and access to suitable patient populations, with a focus on enhancing understanding, diagnosis, and treatment of NF to benefit service members, veterans, and the public. This funding opportunity, totaling approximately $1.6 million for the award, encourages collaborative proposals involving academia, industry, and military branches, with key deadlines for pre-applications on September 12, 2024, and full applications by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    CDMRP Neurofibromatosis New Investigator Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis New Investigator Award to support innovative research in neurofibromatosis (NF). This grant aims to foster the development of early-stage investigators and facilitate the transition of established researchers from other fields into NF research, with a focus on enhancing understanding, diagnosis, and treatment of NF. Eligible applicants include both early-stage and established investigators, and while prior experience in NF research is not required, collaboration with experienced researchers is encouraged. The total estimated funding for this program is $2,880,000, with up to four awards expected, each allowing for direct costs not exceeding $450,000 over a maximum of three years. Interested applicants must submit a pre-application by October 3, 2024, followed by a full application, and can reach the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Synergistic Idea Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research Acquisition Activity, is offering the Neurofibromatosis Synergistic Idea Award, a federal grant aimed at fostering collaborative research projects focused on neurofibromatosis (NF). This award encourages innovative, multidisciplinary approaches involving two or three Principal Investigators (PIs) to address significant challenges in NF research, with an emphasis on developing new therapeutics and enhancing research capacity. With an estimated total program funding of $6.4 million for FY24 and the expectation of awarding two grants, interested applicants must submit a pre-application letter of intent by September 12, 2024, followed by full applications due by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    CDMRP Neurofibromatosis Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the Neurofibromatosis Early Investigator Research Award, a federal grant aimed at supporting innovative research in neurofibromatosis (NF). This opportunity is specifically designed for early-stage investigators to develop research projects under the guidance of experienced mentors, focusing on understanding, diagnosing, and treating NF1, NF2, and schwannomatosis disorders. With a total estimated program funding of $640,000 and an expected two awards, each grant will not exceed $200,000 over a performance period of two years. Interested applicants must submit their proposals by October 3, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Exploration - Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Multiple Sclerosis Exploration - Hypothesis Development Award (MSRP EHDA), aimed at fostering innovative research in the field of multiple sclerosis (MS). This grant program supports high-risk, high-gain research concepts that challenge existing paradigms and lay the groundwork for future scientific investigations, with a focus on areas such as central nervous system repair and mechanisms contributing to MS etiology. The total estimated funding for this program is approximately $2 million, with an expected eight awards, and applications must follow a two-step submission process, including a pre-application due by June 10, 2024, and a full application due by October 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    NFRP Outreach and Invitation for Response
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    DoD Bone Marrow Failure, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Bone Marrow Failure Research Program (BMFRP) Investigator-Initiated Research Award, aimed at advancing research on bone marrow failure (BMF) diseases. This grant opportunity includes two funding levels: Funding Level 1 (FL1) focuses on developing mature ideas and translating discoveries into clinical applications, while Funding Level 2 (FL2) supports efforts to facilitate Investigational New Drug (IND) applications for promising therapeutic candidates. With a total estimated funding of $2.44 million available for two awards, the program encourages innovative and collaborative research proposals that address critical questions in BMF disease management. Interested applicants must submit a pre-application by July 17, 2024, with the full application due by October 9, 2024; for assistance, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Rare Cancers, Idea Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 Rare Cancers Idea Development Award to support innovative research aimed at advancing the understanding and treatment of rare cancers. This grant opportunity encourages proposals that focus on understanding molecular pathways, developing tumor-specific models, or identifying novel therapies, with an emphasis on research that can significantly impact patient outcomes. The total funding available for this program is approximately $17.5 million, with individual awards capped at $350,000 over a three-year period, and applications are due in two stages: a pre-application by June 17, 2024, and a full application by September 23, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Multiple Sclerosis, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Clinical Trial Award to support clinical trials aimed at improving treatment and management of multiple sclerosis (MS). This funding opportunity encourages innovative trials that may include new pharmacologic agents, devices, or emerging technologies, with a total estimated program funding of $8 million and the expectation of awarding three grants. Eligible applicants include unrestricted entities, and the funding levels are set at a maximum of $2 million for small-scale trials and $4 million for larger-scale studies, with a pre-application deadline of June 10, 2024, and a full application deadline of October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.